Alison P. Thomas

Learn More
There is evidence that vascular endothelial growth factor (VEGF) contributes to solid tumor growth through the promotion of both angiogenesis and tumor vascular permeability. To abrogate VEGF signaling, we developed a small molecular weight inhibitor of VEGF receptor tyrosine kinase (RTK) activity that was compatible with chronic oral administration.(More)
Sixty-eight new conditional cell cycle mutants have been isolated on the basis of their terminal cellular morphology (‘dumbbells’). Fifteen mutants falling into nine complementation groups, were grossly defective in DNA replication and have been assigned the provisional gene symboldbf (fordumbbellformer). Dbf1 and2 stop DNA synthesis immediately on transfer(More)
A series of substituted 4-anilinoquinazolines and related compounds were synthesized as potential inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt and KDR) tyrosine kinase activity. Enzyme screening indicated that a narrow structure-activity relationship (SAR) existed for the bicyclic ring system, with quinazolines, quinolines, and(More)
On the basis of an extension of the literature lead 1, a series of benzimidazoles have been synthesized and shown to be angiotensin II (AII) receptor antagonists. The structure-activity relationships of these new antagonists have been explored and the key binding interactions defined. Molecular mechanics calculations were carried out on analogues of(More)
Two new mutantsdbf3 and4, are specifically defective in DNA synthesis. When synchronous cultures ofdbf4 were transferred from the permissive to restrictive temperature before the start of the S phase, no DNA synthesis occurred. However when switched after the beginning of DNA replication, the cells completed that round of synthesis.Dbf4 therefore(More)
  • 1